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There is accumulating evidence to indicate that dur-
ing the early years of renal replacement therapy, peri-
toneal dialysis (PD) provides an equivalent, if not
superior, mode of dialysis to hemodialysis (HD) for a
substantial number of patients [1, 2]. The benefit of PD,
however, appears to be limited to the first three or four
years, and the majority of patients switch therapy to HD
because of technique failure. The causes of this treatment
failure are multifactorial and include recurrent episodes
of peritonitis, loss of residual renal function, and loss
of peritoneal function [3]. The most common change in
peritoneal function is a loss of ultrafiltration capacity, al-
though a reduction in solute clearance is not an infre-
quent occurrence [4–6]. The causes of such functional
changes are poorly understood but there is increasing ev-
idence that they are related to changes in the structure of
the membrane which correlates in most patients with the
longevity of dialysis [7–10], although other factors clearly
are influential.
Structural changes include the loss of mesothelial cells,
an increase in the thickness of the submesothelial com-
pact zone, and a plethora of vascular changes, which
range from classical small vessel atherosclerosis to venu-
lar changes. The etiology of these structural changes,
however, remains speculative and includes the uremic
process itself, recurrent infections, and the continuous
exposure of the membrane to bioincompatible dialysis
fluids [11].
Dialysis fluid has long been recognized as “bioincom-
patible” with the homeostasis of the peritoneal cavity
[12–16]. A low pH, hyperosmolar fluid containing lactate
as a buffering agent, and glucose degradation products
(GDP) as a byproduct of production will inevitably have
long-term negative pathophysiologic consequences [17,
18, 19]. By definition however, the fluid cannot be phys-
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iologic [16]. The challenge in the design of new fluids is
to reduce the components with the greatest potential to
cause long-term pathologic events while maintaining the
efficacy of the fluid as a tool for dialysis.
The article will examine current data from the biopsy
registry and will revisit those conclusions drawn from the
original publication. It will also take the opportunity to
examine, in paired specimens, the comparative changes in
visceral and parietal peritoneum. Finally, it will examine
in greater detail the evidence for an increase in blood
vessel number in specimens taken from PD patients.
METHODS
All samples were collected and fixed in accordance
with a standardized protocol and shipped to a central
laboratory for processing, staining, and analysis [7]. Nor-
mal samples were obtained from living kidney donors
with no history of previous abdominal pathology. Uremic
samples were from predialysis patients or from HD pa-
tients at catheter insertion (in no case had any of these
patients undergone PD). Biopsies from PD patients were
categorized into four groups: (1) Samples obtained at
transplantation (considered to be random samples); (2)
samples obtained during incidental surgery (hernia re-
pair or cholecystectomy); (3) samples obtained at surgery
related to PD problems (catheter malposition, catheter
replacement); and (4) samples obtained from patients
with membrane failure.
Mesothelial cell analysis was carried out using images
from scanning and transmission electron micrographs
(SEM and TEM). Submesothelial compact zone thick-
ness and percentage vasculopathy [7] were measured
from semithin sections (0.35 lm) stained with Toluidine
blue and Periodic Acid Thiocarbohydrazide Silver Pro-
teinate Silver Enhancement (PATCH-SP-SE), respec-
tively. Visceral and parietal peritoneal morphology were
compared in paired samples from the same subject. A
histopathologist blinded to the clinical status of the pa-
tient carried out the analysis.
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Fig. 1. (A) Normal parietal peritoneum. There is a surface layer of flattened, cohesive mesothelial cells bearing microvilli and with indistinct
cytoplasm containing occasional small vesicles. Nuclei are relatively inconspicuous and nucleoli are not seen. There is a submesothelial compact
zone of mature collagen fibers. Toluidine blue stain. (B) Parietal peritoneum from a patient treated only by hemodialysis. The mesothelial cells
show “reactive” changes. While cohesive, they are enlarged and appear rounded or cuboidal. The cytoplasm is prominent and finely granular, and
the nuclei are irregular with prominent nucleoli and marginated chromatin. There is thickening of the submesothelial compact zone. Toluidine blue
stain. (C) Parietal peritoneum from a patient treated with peritoneal dialysis. The mesothelial cells show reactive changes similar to those in B, but
they are beginning to separate, both from each other and from the underlying stroma. Toluidine blue stain. (D) Parietal peritoneum from a patient
treated with peritoneal dialysis. There is thickening of the submesothelial compact zone by coarse collagen bundles and the overlying mesothelium
shows degenerative changes superimposed on the reactive changes seen in B and C. The mesothelial cells are pale, rounded, and discohesive and
some are shedding from the surface. Toluidine blue stain.
RESULTS
Peritoneal membrane morphology
Normal individuals. Fifteen normal parietal speci-
mens were examined. All had intact mesothelial cell sur-
face covering. Mesothelial cells seen “en face” by SEM
were of polygonal appearance with a dense covering of
surface microvilli. In section, they were of a flattened ap-
pearance (Fig. 1A), and TEM revealed cell-cell contact
maintained by tight junctions. The median thickness of
the submesothelial compact zone was 40 lm (interquar-
tile range [IQR], 30 to 70 lm). A detailed analysis of the
vascular structures in the submesothelial compact zone
failed to identify any vasculopathy changes in either ar-
teries or venules.
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Fig. 2. Thickness of the submesothelial compact zone (microns) in pa-
tients donating a kidney for transplantation, patients with uremia un-
dergoing catheter insertion and patients with end-stage renal disease
who have only had hemodialysis therapy. For each box plot, median
values are represented by the line within the box. The box represents
50% of the values (the 25th and 75th centiles), with the bars represent-
ing the highest and lowest values, excluding outliers () and extremes
(∗).
Pre-dialysis and hemodialysis patients. In 27 parietal
samples recovered from this group of patients, surface
mesothelium was absent in 18.1%. In those patients with
intact mesothelium, the cells sometimes assumed a re-
active state, with increased apical-basolateral diameter
(Fig. 1B), changes in surface microvilli, and an increase
in intracytoplasmic organelles. In other samples mesothe-
lial cells appeared rounded and degenerate.
Parietal specimens taken from these patients showed
significant thickening of the submesothelial compact zone
(median thickness 150 lm (90 to 230 lm) (Fig. 2). Ex-
amination of the submesothelial vasculature showed a
characteristic subendothelial hyalinization in 29%, which
appeared to be mostly in venules. Grading of this vascu-
lopathy indicated that in the majority of cases the vas-
culopathy was of Grade 1 or 2 [7]. Occasional arterioles
showed evidence of intimal atherosclerotic changes.
Peritoneal dialysis patients. In samples obtained from
patients on PD, surface mesothelial cells showed a change
in morphology of a similar nature to that seen in uremic
patients (Fig. 1C). In addition, a significant proportion of
the cells appeared degenerate with loss of nuclear density
and a paucity of intracytoplasmic organelles. In a small
percentage of patients, cells became columnar in appear-
ance, vacuolated, and discohesive (Fig. 1D).
As previously described [7], parietal submesothelial
compact zone thickness increased with time on PD. Anal-
ysis by origin of sample, however, demonstrated that sam-
ples obtained at random from patients undergoing renal
transplantation had least thickening of their submesothe-
lial compact zone at 180 lm (IQR, 99 to 255 lm; N = 59);
patients’ biopsies at the time of incidental surgery had
a median thickness of 280 lm (IQR, 190 to 360 lm;
N = 19). Patients undergoing surgery for PD-related
problems had a further and significant increase in com-
pact zone thickness with a median of 420 lm (IQR, 240 to
750 lm; N = 57). The greatest increase in submesothelial
compact zone thickening was found in that group of pa-
tients with membrane dysfunction 700 lm (IQR, 460 to
1100 lm; N = 27). The majority of this group consisted of
patients with loss of ultrafiltration and solute clearance.
Changes in blood vessel structure were morphologi-
cally similar in biopsies from PD patients to those changes
identified in uremic patients, although the prevalence of
changes increased on PD.
The lowest proportion of vasculopathic changes in
biopsies from PD patients were seen in the patients biop-
sied at transplantation. Almost 50% of this group of
patients showed no evidence of vasculopathy. In the re-
mainder most of the changes were of Grades 1 and 2
(Table 1). In the membrane dysfunction group, however,
almost 70% of the patients had Grade 4 changes with
obliteration of vessel lumina.
Further analysis of vasculopathy and fibrosis were
made in respect of patient age. There was no relation-
ship between the age of the patient and the thickness of
the submesothelial compact zone or with respect to the
presence or grade of vasculopathy.
Comparison of visceral and parietal
peritoneum specimens
Thirty-eight PD patients had samples taken from both
visceral and parietal membranes. Compact zone thick-
ness as well as degree of vasculopathy was measured in
each sample. The median thickness of the visceral samples
was 20 lm (IQR, 10 to 80), while the median thickness
of the parietal samples was 505 lm (IQR, 180 to 850)
(P = 0.0001, Wilcoxon signed-rank test) (Fig. 3). The me-
dian thickness of normal parietal peritoneum was 50 lm
(IQR, 25 to 135) for comparison. Blood vessel changes
were graded 1 to 4 as previously defined [7]. Vasculopa-
thy was generally more prevalent and of greater sever-
ity in parietal than in visceral samples (chi-square test,
P = 0.002) (Table 2).
DISCUSSION
For the purpose of understanding the way in which
changes in the peritoneal membrane impact on the home-
ostasis of the peritoneal cavity and on the dialytic func-
tion of the membrane, it is important to define those
elements that make up the membrane. The interface
between the peritoneal cavity and the membrane begins
at the mesothelial monolayer and its basement mem-
brane. The submesothelial compact zone bridges the
space between the mesothelial cells and the underlying
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Table 1. Grade of vasculopathy and origin of sample
No
vasculopathy Grade 1 Grade 2 Grade 3 Grade 4
Donor N = 13 13 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0)%
Catheter insertion N = 20 11 (55%) 3 (15%) 3 (15%) 3 (15%) 0 (0%)
Transplant N = 118 75 (63.6%) 21 (17.8%) 16 (13.6%) 2 (1.7%) 4 (3.4%)
Incidental surgery N = 28 13 (46.4%) 3 (10.7%) 10 (35.7%) 0 (0%) 2 (7.1%)
Catheter change N = 59 16 (27.1%) 6 (10.2%) 9 (15.3%) 10 (16.9%) 18 (30.5%)
Membrane failure N = 27 3 (11.1%) 0 (0%) 3 (11.1%) 3 (11.1%) 18 (66.7%)
Grade 1 = Thickening of lumen < 7 microns.
Grade 2 = Thickening of lumen > 7 microns, no luminal distortion.
Grade 3 = Thickening with luminal distortion.
Grade 4 = Obliteration of lumen.
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Fig. 3. Thickness of the submesothelial compact zone (microns) in pa-
tients whose samples were obtained in a random manner (during trans-
plantation or incidental surgery), and those obtained when patients
were having problems with peritoneal dialysis therapy (those under-
going catheter replacement or having surgery due to membrane dys-
function). For each box plot, median values are represented by the line
within the box. The box represents 50% of the values (the 25th and
75th centiles), with the bars representing the highest and lowest values.
Outliers and extreme values are not charted.
Table 2. Grade of vasculopathy: paired visceral and parietal samples
No Grade Grade Grade Grade
Parietal vasculopathy 1 2 3 4
Visceral
No vasculopathy 10 2 4 3 5
Grade 1 0 1 0 1 3
Grade 2 0 0 1 1 3
Grade 3 0 0 0 1 2
Grade 4 0 0 0 0 1
vascular plexus. Dialysis takes place between the
mesothelial cell surface facing the peritoneal cavity and
the inner surface of the peritoneal capillary endothelial
cell. Thus, any change in the structure of this membrane,
either quantitative or qualitative, may have a significant
impact on dialysis.
The relative importance of visceral as opposed to pari-
etal peritoneal membrane in terms of dialysis function
remains speculative. Such evidence as exists dictates that
dialysis takes place mainly across the parietal peritoneal
membrane [20, 21]. Most biopsies of human peritoneum
are taken from the parietal membrane. Most animal stud-
ies (in particular vascular dynamics) are carried out on
the visceral component. We present evidence from paired
human biopsies which indicates that changes in the vis-
ceral membrane are significantly less pronounced than
those from the corresponding parietal membrane (Fig. 4)
[22]. The parietal membrane demonstrates a significant
greater tendency to increase the thickness of its subme-
sothelial compact zone and exhibits a significantly greater
prevalence of vasculopathy than does the corresponding
visceral membrane. In view of this, great caution should
be taken in translating the findings of experimental stud-
ies on visceral peritoneum to clinical implications for hu-
man parietal peritoneum. Interestingly, and in contrast,
encapsulating peritoneal sclerosis (EPS), when it occurs,
is almost exclusively a feature of the visceral peritoneal
membrane [10, 23], suggesting that a different patho-
genetic mechanism may be involved.
Numerous publications have highlighted the loss of
mesothelial cells from the peritoneal surface as an almost
universal feature in patients on continuous ambulatory
peritoneal dialysis (CAPD). Most of these publications,
however, are based on unquantified evidence and a small
sample number [24–27]. The degree of care applied when
taking biopsies is also unclear. We found that the loss of
mesothelium correlated with the extent of vasculopathy
and with an increased thickness of the submesothelial
compact zone. In addition, the remaining mesothelium
was, in most biopsies, of abnormal appearance, showing
morphologic changes of activation and/or degeneration
[27] (Fig. 1). Degenerate mesothelial cells were discohe-
sive and more likely to shed into the peritoneal cavity.
A recent study [28] has examined shed mesothelial cells
isolated from PD effluent and compared them with oth-
ers grown from omental biopsies. With time on dialy-
sis there appeared to be a possible transdifferentiation
of mesothelial cells from an epithelioid to a mesenchy-
mal/fibroblastic phenotype. Accompanying this change
was a decrease in cytokeratin expression and an increase
in vimentin expression. According to earlier studies,
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Fig. 4. Comparison of the thickness (in microns) of paired samples of
visceral and parietal peritoneum taken simultaneously.
however, an increased vimentin expression was fre-
quently seen in cultured mesothelial cells when compared
to in situ cells [29]. In addition, the switch between keratin
and vimentin expression appears to be reversible accord-
ing to the culture conditions and the presence of growth
factors [30].
A switch in phenotype from epithelioid to fibroblastic
appeared to confer on these cells a migratory phenotype,
allowing them to move into the submesothelial stroma
(compact zone), where they may contribute directly to
the fibrotic process [28]. This proposed direction of cell
movement is in contrast to the previous hypothesis that
mesothelial cells are replaced from stromal cells that mi-
grate in an “upward” direction [31, 32]. This has been
challenged recently, however, by labeling studies suggest-
ing that the replacement of mesothelial cells lost from
the surface occurs by the proliferation of remaining sur-
face cells [33]. We were unable to identify in vivo similar
fibroblastic phenotypic changes in the mesothelial cells
seen in over 60 biopsy specimens. The morphologic ap-
pearance of samples from the present study suggests that
the most common phenotypic change seen in mesothelial
cells from biopsies of patients on PD was an increase in
intracellular organelles, or that the cells took on a degen-
erate appearance with loss of cytoplasmic organization.
It is therefore difficult to explain the differences between
these studies and raises the question of whether efflu-
ent cells are truly representative of the remaining surface
mesothelial cells. The loss of cells from the surface of
the peritoneal membrane is likely to be due to a change
in their phenotype, which allows them to detach and be
washed out in the PD effluent, as opposed to migration
and invasion of the stroma.
Numerous studies have identified changes to the com-
pact zone that lies beneath the mesothelial monolayer
[7, 10, 23–27, 33]. It is accepted that an increase in fibrosis
occurs within this region and that it is broadly related to
time on dialysis. The Biopsy Registry has identified that
this increased thickness precedes PD therapy (i.e., it is
present as the result of uremia in both predialysis and pa-
tients treated only with HD) [7]. In addition, the degree of
fibrosis varies between individuals: in some cases, individ-
uals exhibiting a 10-fold increase in thickness after eight
years on dialysis, and others barely a two-fold change over
the same period of time. We were able to demonstrate
that those patients with a history of problems with PD
(multiple infections, malfunctioning catheters, or declin-
ing membrane function) were most likely to have signif-
icant thickening of the submesothelial compact zone [7].
The change in membrane thickness is therefore likely to
be multifactorial and the result of the variety of patho-
logic insults endured by the membrane during time on
PD.
The third, and arguably the most important component
of the peritoneal membrane is the vascular bed. Anatom-
ically, the bulk of this lies at the junction of the subme-
sothelial compact zone and its underlying adipose tissue
or serosa. Some vessels, however, lie within the compact
zone. In the visceral membrane where there is little or
no compact zone, and the vessels may be adjacent to the
basement membrane of the mesothelial monolayer.
Changes to the vessels were first carefully catego-
rized in a small study by Honda et al [9]. They noted
a subendothelial hyalinization in small vessels thought
to be venules. At its most extreme this resulted in
obliteration of vessels. In addition, those vessels with
structural change showed an accumulation of advanced
glycation end products (AGE). Finally, they demon-
strated in a small number of patients a correlation
between this “vasculopathy” and a decrease in ultrafil-
tration across the peritoneal membrane. We were able
to confirm these findings in a larger study [7]. The suben-
dothelial hyalinization appears to be a process that begins
during the progression of uremia and is seen in its mild
and moderate forms before PD begins. The imposition of
PD then accelerates the process. But, as with thickening
of the compact zone, the changes are not universal across
the PD population and affect those individuals who expe-
rience recurrent problems with PD. Analysis of the data
from the biopsy registry demonstrates a highly significant
correlation between the vasculopathy and thickening of
the compact zone. The nature of the correlation suggests
that the vasculopathy may be a major factor in influencing
fibrosis. It may be that a feature of the obliterative vas-
culopathy is ischemia, which is known from other studies
to result in fibrosis [34].
An increase in vessel numbers has also been identi-
fied in human biopsy studies [35]. This change appears
to correlate with an increase in fibrous tissue. Using
nitric oxide synthase (NOS) activity as a surrogate marker
of vessel number, in addition to direct counting, Combet
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et al [36] have confirmed these findings, demonstrating a
quantitative increase in NOS activity with time on PD. In
the same study, the presence of AGE in the peritoneal
membrane colocalized in blood vessels with vascular en-
dothelial growth factor (VEGF), a growth factor associ-
ated with increased blood vessel permeability previously
demonstrated to be locally produced by the peritoneal
membrane of patients on PD [37].
Parallel studies in animal models of PD (with or with-
out uremia) have demonstrated the ability of glucose-
based dialysis solutions to induce new vessel formation in
the visceral peritoneum. A role for transforming growth
factor b1 (TGF-b1) and VEGF in the induction of fibro-
sis and neovascularization has been suggested by recent
gene transfer studies, although whether these short-term
studies can be used to explain the long-term changes of
the peritoneal membrane in humans has yet to be estab-
lished [38–41].
CONCLUSION
The data emerging from the Biopsy Registry indi-
cate that changes to the morphology of the peritoneal
membrane begin during the period of uremia that pre-
cedes renal replacement therapy. These changes per-
sist but do not appear to progress appreciably during
hemodialysis. With the introduction of PD, however,
there is, in some patients, a progressive worsening both
of compact zone fibrosis and of vasculopathy. The acqui-
sition of random samples from patients undergoing renal
transplantation represents a true reflection of the changes
during uncomplicated dialysis. These changes contrast
sharply with the appearance of the membrane in those
patients who develop problems with PD and/or develop
membrane failure. Thus, not all patients on PD inevitably
develop progressive membrane changes. The availability
of paired visceral and parietal samples also gives insight
into the lack of correlation between the two sites in terms
of morphologic changes. This should lead to caution when
interpreting membrane changes in animal models (most
of which focus on the visceral peritoneum), as well as
indicating that the development of EPS (a visceral mem-
brane phenomenon) may not be a direct progression of
simple fibrosis.
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